伊布替尼-话题@MedSci

#伊布替尼#

88篇内容 | 4028人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1288766, encodeId=57ab1288e66a2, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2018 ASH速览】杨申淼教授：伊布替尼真实世界研究，进一步证明临床有效性及长期安全性, objectType=article, longId=155024, objectId=611a1550242a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=611a1550242a, replyNumber=0, likeNumber=43, createdTime=2018-12-05, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=611a1550242a, moduleTitle=【2018 ASH速览】杨申淼教授：伊布替尼真实世界研究，进一步证明临床有效性及长期安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=611a1550242a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288765, encodeId=b70d1288e6557, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2018 ASH】张薇教授盘点BTKi伊布替尼联合治疗亮点, objectType=article, longId=154710, objectId=3672154e10c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3672154e10c1, replyNumber=0, likeNumber=40, createdTime=2018-12-01, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3672154e10c1, moduleTitle=【2018 ASH】张薇教授盘点BTKi伊布替尼联合治疗亮点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3672154e10c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288764, encodeId=e3101288e64b5, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2018 ASH】徐卫教授速递：伊布替尼在慢性淋巴细胞白血病领域治疗取得哪些突破？, objectType=article, longId=154583, objectId=9a80154583ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a80154583ac, replyNumber=0, likeNumber=78, createdTime=2018-11-30, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a80154583ac, moduleTitle=【2018 ASH】徐卫教授速递：伊布替尼在慢性淋巴细胞白血病领域治疗取得哪些突破？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a80154583ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288763, encodeId=39f51288e63d6, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=强生公司寻求在欧洲扩大伊布替尼的适应症, objectType=article, longId=153631, objectId=eeed153631ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eeed153631ca, replyNumber=0, likeNumber=73, createdTime=2018-11-17, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eeed153631ca, moduleTitle=强生公司寻求在欧洲扩大伊布替尼的适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eeed153631ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288762, encodeId=a9701288e62fa, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=2018年IWWM 会议现场直达：伊布替尼治疗华氏巨球蛋白血症突破性进展！, objectType=article, longId=152793, objectId=d2de152e93c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2de152e93c7, replyNumber=0, likeNumber=124, createdTime=2018-11-07, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2de152e93c7, moduleTitle=2018年IWWM 会议现场直达：伊布替尼治疗华氏巨球蛋白血症突破性进展！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2de152e93c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288761, encodeId=0f771288e619b, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2018 CSH】马军教授：伊布替尼进医保，高效安全可负担，更多淋巴瘤患者进入无化疗时代！, objectType=article, longId=152390, objectId=2ade15239044, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ade15239044, replyNumber=0, likeNumber=75, createdTime=2018-11-01, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ade15239044, moduleTitle=【2018 CSH】马军教授：伊布替尼进医保，高效安全可负担，更多淋巴瘤患者进入无化疗时代！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ade15239044)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288760, encodeId=ba7c1288e6075, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【CSH重磅发布】伊布替尼一线治疗CLL研究RESONATE-2发布55个月随访结果, objectType=article, longId=152263, objectId=452d1522636d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=452d1522636d, replyNumber=0, likeNumber=76, createdTime=2018-10-31, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=452d1522636d, moduleTitle=【CSH重磅发布】伊布替尼一线治疗CLL研究RESONATE-2发布55个月随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=452d1522636d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288759, encodeId=e8891288e596a, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=CANCER CHEMOTH PHARM ：PH调节剂奥美拉唑对伊布替尼影响几何？, objectType=article, longId=146157, objectId=748714615e75, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=748714615e75, replyNumber=0, likeNumber=72, createdTime=2018-08-10, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=748714615e75, moduleTitle=CANCER CHEMOTH PHARM ：PH调节剂奥美拉唑对伊布替尼影响几何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=748714615e75)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288758, encodeId=92101288e58d7, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2018年EHA抢鲜报道】伊布替尼在CLL / SLL患者中的一线治疗：RESONATE-2研究的4年经验, objectType=article, longId=140718, objectId=caa0140e18ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=caa0140e18ef, replyNumber=0, likeNumber=44, createdTime=2018-06-15, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=caa0140e18ef, moduleTitle=【2018年EHA抢鲜报道】伊布替尼在CLL / SLL患者中的一线治疗：RESONATE-2研究的4年经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=caa0140e18ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288757, encodeId=26bd1288e57f5, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2018年EHA抢鲜报道】伊布替尼联合Obinutuzumab用于CLL一线治疗：ICLL07 FILO研究, objectType=article, longId=140367, objectId=366814036eaa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=366814036eaa, replyNumber=0, likeNumber=69, createdTime=2018-06-10, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=366814036eaa, moduleTitle=【2018年EHA抢鲜报道】伊布替尼联合Obinutuzumab用于CLL一线治疗：ICLL07 FILO研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=366814036eaa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288756, encodeId=06421288e5622, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=MYD88突变对伊布替尼治疗敏感性影响几何？, objectType=article, longId=140243, objectId=555914024311, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=555914024311, replyNumber=0, likeNumber=64, createdTime=2018-06-09, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=555914024311, moduleTitle=MYD88突变对伊布替尼治疗敏感性影响几何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=555914024311)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288755, encodeId=d2201288e5591, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=Haematologic：真实世界经验——NPP计划下伊布替尼治疗CLL的国际经验, objectType=article, longId=140242, objectId=1bd1140242b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bd1140242b4, replyNumber=0, likeNumber=43, createdTime=2018-06-09, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bd1140242b4, moduleTitle=Haematologic：真实世界经验——NPP计划下伊布替尼治疗CLL的国际经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bd1140242b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288754, encodeId=c3561288e54f0, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=NEJM：伊布替尼联合利妥昔单抗用于治疗瓦尔登斯特伦巨球蛋白血症, objectType=article, longId=140055, objectId=083e140055f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=083e140055f2, replyNumber=0, likeNumber=82, createdTime=2018-06-07, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=083e140055f2, moduleTitle=NEJM：伊布替尼联合利妥昔单抗用于治疗瓦尔登斯特伦巨球蛋白血症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=083e140055f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288753, encodeId=b4321288e538d, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2018EHA抢先看】一种新方法：或有助于优化CLL伊布替尼联合治疗策略, objectType=article, longId=139495, objectId=8d8c13949555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d8c13949555, replyNumber=0, likeNumber=71, createdTime=2018-06-01, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d8c13949555, moduleTitle=【2018EHA抢先看】一种新方法：或有助于优化CLL伊布替尼联合治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d8c13949555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288752, encodeId=10941288e523d, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=Blood：伊布替尼单药治疗慢性淋巴细胞白血病5年随访结果公布！, objectType=article, longId=137617, objectId=231413e617e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=231413e617e4, replyNumber=0, likeNumber=56, createdTime=2018-05-10, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=231413e617e4, moduleTitle=Blood：伊布替尼单药治疗慢性淋巴细胞白血病5年随访结果公布！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=231413e617e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288751, encodeId=4ea91288e51d2, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=NEJM：伊布替尼联合维奈妥拉可显著改善复发难治性套细胞淋巴瘤预后, objectType=article, longId=134263, objectId=786e13426328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=786e13426328, replyNumber=0, likeNumber=67, createdTime=2018-04-06, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=786e13426328, moduleTitle=NEJM：伊布替尼联合维奈妥拉可显著改善复发难治性套细胞淋巴瘤预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=786e13426328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288750, encodeId=ebbf1288e5097, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=粘着斑激酶抑制剂克服了骨髓微环境中套细胞淋巴瘤对伊布替尼的耐药性, objectType=article, longId=133938, objectId=84b21339380a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b21339380a, replyNumber=0, likeNumber=82, createdTime=2018-04-02, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b21339380a, moduleTitle=粘着斑激酶抑制剂克服了骨髓微环境中套细胞淋巴瘤对伊布替尼的耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84b21339380a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288749, encodeId=38d51288e49c7, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=P53基因重排/突变的白血病非淋巴结套细胞淋巴瘤对利妥昔单抗/伊布替尼组合疗法高度敏感, objectType=article, longId=133937, objectId=40e013393ec7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40e013393ec7, replyNumber=0, likeNumber=74, createdTime=2018-04-02, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40e013393ec7, moduleTitle=P53基因重排/突变的白血病非淋巴结套细胞淋巴瘤对利妥昔单抗/伊布替尼组合疗法高度敏感, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40e013393ec7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288748, encodeId=5ad51288e4813, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=初治和复发/难治性慢性淋巴细胞白血病使用伊布替尼单药治疗的5年经验, objectType=article, longId=133936, objectId=36181339363b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36181339363b, replyNumber=0, likeNumber=81, createdTime=2018-04-02, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36181339363b, moduleTitle=初治和复发/难治性慢性淋巴细胞白血病使用伊布替尼单药治疗的5年经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36181339363b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288747, encodeId=5e0f1288e47cb, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=重磅：伊布替尼的出血副作用得到了解决！, objectType=article, longId=133935, objectId=ca85133935b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca85133935b4, replyNumber=0, likeNumber=86, createdTime=2018-04-02, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca85133935b4, moduleTitle=重磅：伊布替尼的出血副作用得到了解决！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca85133935b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

伊布替尼

2020-05-29

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2018 ASH速览】杨申淼教授：伊布替尼真实世界研究，进一步证明临床有效性及长期安全性

2018-12-05

柳叶一刀 (审核中...)

前往app查看评论内容

#伊布替尼#

【2018 ASH】张薇教授盘点BTKi伊布替尼联合治疗亮点

2018-12-01

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2018 ASH】徐卫教授速递：伊布替尼在慢性淋巴细胞白血病领域治疗取得哪些突破？

2018-11-30

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

强生公司寻求在欧洲扩大伊布替尼的适应症

2018-11-17

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

2018年IWWM 会议现场直达：伊布替尼治疗华氏巨球蛋白血症突破性进展！

2018-11-07

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2018 CSH】马军教授：伊布替尼进医保，高效安全可负担，更多淋巴瘤患者进入无化疗时代！

2018-11-01

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【CSH重磅发布】伊布替尼一线治疗CLL研究RESONATE-2发布55个月随访结果

2018-10-31

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

CANCER CHEMOTH PHARM ：PH调节剂奥美拉唑对伊布替尼影响几何？

2018-08-10

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2018年EHA抢鲜报道】伊布替尼在CLL / SLL患者中的一线治疗：RESONATE-2研究的4年经验

2018-06-15

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2018年EHA抢鲜报道】伊布替尼联合Obinutuzumab用于CLL一线治疗：ICLL07 FILO研究

2018-06-10

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

MYD88突变对伊布替尼治疗敏感性影响几何？

2018-06-09

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

Haematologic：真实世界经验——NPP计划下伊布替尼治疗CLL的国际经验

2018-06-09

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

NEJM：伊布替尼联合利妥昔单抗用于治疗瓦尔登斯特伦巨球蛋白血症

2018-06-07

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2018EHA抢先看】一种新方法：或有助于优化CLL伊布替尼联合治疗策略

2018-06-01

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

Blood：伊布替尼单药治疗慢性淋巴细胞白血病5年随访结果公布！

2018-05-10

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

NEJM：伊布替尼联合维奈妥拉可显著改善复发难治性套细胞淋巴瘤预后

2018-04-06

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

粘着斑激酶抑制剂克服了骨髓微环境中套细胞淋巴瘤对伊布替尼的耐药性

2018-04-02

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

P53基因重排/突变的白血病非淋巴结套细胞淋巴瘤对利妥昔单抗/伊布替尼组合疗法高度敏感

2018-04-02

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

初治和复发/难治性慢性淋巴细胞白血病使用伊布替尼单药治疗的5年经验

2018-04-02

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

重磅：伊布替尼的出血副作用得到了解决！

2018-04-02

科室
- - 订阅+
  - 更多科室
工具
服务